• I Cancer Drug Development.- 1 Cancer Drug Development: Challenges in a Competitive Market.- II Chemistry and Cell Biology of the Proteasome.- 2 Introduction to the Proteasome and Its Inhibitors: Biochemistry and Cell Biology.- 3 Structures of the Yeast Proteasome Core Particle in Complex with Inhibitors.- 4 Natural Product and Synthetic Proteasome Inhibitors.- 5 Other Proteasome Inhibitors.- 6 The Proteasome in Cell-Cycle Regulation.- 7 Proteasome Inhibition and Apoptosis.- 8 The Proteasome and the COMPARE Algorithm.- III Rationale for Proteasome Inhibitors in Cancer.- 9 The Proteasome in Cancer Biology and Therapy.- 10 Radiosensitization and Proteasome Inhibition.- 11 Proteasome-Dependent Regulation of NF-?B Activation: Molecular Targeting of Chemotherapy Resistance.- 12 Bortezomib with Taxanes.- 13 Proteasome Inhibitor Therapy in a Brain Tumor Model.- 14 Anthracyclines and Bortezomib.- 15 TNF-Related Apoptosis-Inducing Ligand (TRAIL): Combination with Proteasome Inhibition For Anticancer Therapy?.- 16 Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin.- 17 The Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation.- 18 Function(s) of the Ubiquitin—Proteasome System in Retrovirus Budding.- IV Clinical Trials.- 19 Preclinical Development of Bortezomib (VELCADE™): Rationale for Clinical Studies.- 20 Phase I Trials: Bortezomib Alone and in Combination With Standard Chemotherapies.- 21 Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy.- 22 Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma.

"Authoritative and illuminating..." - Tumori